Healthcare / BiotechnologyNasdaqGM
$4.20
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-51.2M · quality 69.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$170M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-105.9%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.87x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-59.5M · FCF $-51.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Net Income | $-59.5M | $-59.5M | $-52.7M | $-35.3M | $-29.5M | $-39.8M | $-19.5M |
| EBITDA | $-58.7M | $-58.7M | $-51.7M | $-34.8M | $-29.4M | $-39.8M | $-19.5M |
| EPS | — | — | -15.28 | -2.65 | -2.21 | -21.90 | -96.00 |
| Balance Sheet | |||||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | -0.01 | -0.01 | — | — |
| Current Ratio | 13.78 | 13.78 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-51.9M | $-51.9M | $-51.2M | $-34.8M | $-28.1M | $-38.2M | $-18.6M |
| Returns | |||||||
| ROE | -105.9% | -105.9% | -50.7% | 34.7% | 54.2% | -27.0% | 46.2% |
| Valuation | |||||||
| P/B | 1.02 | 1.02 | 0.30 | — | — | — | — |
| Growth & Yield | |||||||
| EPS Growth | — | — | -477.2% | -19.6% | — | 77.2% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+66.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-15.28 → n/d
Residual
+66.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.